Paul E. Wiedeman
Abbott (United States)(US)Abbott Fund(US)
Publications by Year
Research Areas
Peptidase Inhibition and Analysis, Veterinary medicine and infectious diseases, Diabetes Treatment and Management, Toxin Mechanisms and Immunotoxins, Neuropeptides and Animal Physiology
Most-Cited Works
- → 3,5-Bis(trifluoromethyl)pyrazoles: A Novel Class of NFAT Transcription Factor Regulator(2000)120 cited
- → Potent Inhibition of NFAT Activation and T Cell Cytokine Production by Novel Low Molecular Weight Pyrazole Compounds(2001)99 cited
- Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes.(2003)
- → Discovery, Structure−Activity Relationship, and Pharmacological Evaluation of (5-Substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as Potent Dipeptidyl Peptidase IV Inhibitors(2006)61 cited
- → The synthesis and biological evaluation of a novel series of antimicrobials of the oxazolidinone class(2002)60 cited
- → Synthesis of N-arylated oxazolidinones via a palladium catalyzed cross coupling reaction. Application to the synthesis of the antibacterial agent Dup-721(2001)48 cited
- → (+)-Pleuromutilin synthetic studies. Degradative and de novo acquisition of a levorotatory tricyclic lactone subunit(1988)44 cited
- → Crystal Structures of DPP-IV (CD26) from Rat Kidney Exhibit Flexible Accommodation of Peptidase-Selective Inhibitors(2006)42 cited
- → Discovery of 2-[4-{{2-(2S,5R)-2-Cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic Acid (ABT-279): A Very Potent, Selective, Effective, and Well-Tolerated Inhibitor of Dipeptidyl Peptidase-IV, Useful for the Treatment of Diabetes(2006)37 cited
- → Inhibition of p56lckTyrosine Kinase by Isothiazolones(1999)37 cited